261 related articles for article (PubMed ID: 26914704)
1. The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism.
Batista R; Cruvinel-Carloni A; Vinagre J; Peixoto J; Catarino TA; Campanella NC; Menezes W; Becker AP; de Almeida GC; Matsushita MM; Clara C; Neder L; Viana-Pereira M; Honavar M; Castro L; Lopes JM; Carvalho B; Vaz RM; Máximo V; Soares P; Sobrinho-Simões M; Reis RM; Lima J
Int J Cancer; 2016 Jul; 139(2):414-23. PubMed ID: 26914704
[TBL] [Abstract][Full Text] [Related]
2. TERT promoter mutations and rs2853669 polymorphism: prognostic impact and interactions with common alterations in glioblastomas.
Nencha U; Rahimian A; Giry M; Sechi A; Mokhtari K; Polivka M; Schmitt Y; Di Stefano AL; Alentorn A; Labussière M; Sanson M
J Neurooncol; 2016 Feb; 126(3):441-6. PubMed ID: 26608520
[TBL] [Abstract][Full Text] [Related]
3. Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.
Spiegl-Kreinecker S; Lötsch D; Ghanim B; Pirker C; Mohr T; Laaber M; Weis S; Olschowski A; Webersinke G; Pichler J; Berger W
Neuro Oncol; 2015 Sep; 17(9):1231-40. PubMed ID: 25681309
[TBL] [Abstract][Full Text] [Related]
4. TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations.
Labussière M; Di Stefano AL; Gleize V; Boisselier B; Giry M; Mangesius S; Bruno A; Paterra R; Marie Y; Rahimian A; Finocchiaro G; Houlston RS; Hoang-Xuan K; Idbaih A; Delattre JY; Mokhtari K; Sanson M
Br J Cancer; 2014 Nov; 111(10):2024-32. PubMed ID: 25314060
[TBL] [Abstract][Full Text] [Related]
5. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
[TBL] [Abstract][Full Text] [Related]
6. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
[TBL] [Abstract][Full Text] [Related]
7.
Juratli TA; Stasik S; Zolal A; Schuster C; Richter S; Daubner D; Juratli MA; Thowe R; Hennig S; Makina M; Meinhardt M; Lautenschlaeger T; Schackert G; Krex D; Thiede C
Clin Cancer Res; 2018 Nov; 24(21):5282-5291. PubMed ID: 29941484
[No Abstract] [Full Text] [Related]
8. TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas.
Simon M; Hosen I; Gousias K; Rachakonda S; Heidenreich B; Gessi M; Schramm J; Hemminki K; Waha A; Kumar R
Neuro Oncol; 2015 Jan; 17(1):45-52. PubMed ID: 25140036
[TBL] [Abstract][Full Text] [Related]
9. Association between rs2853669 in TERT gene and the risk and prognosis of human cancer: a systematic review and meta-analysis.
Shen N; Lu Y; Wang X; Peng J; Zhu Y; Cheng L
Oncotarget; 2017 Aug; 8(31):50864-50872. PubMed ID: 28881610
[TBL] [Abstract][Full Text] [Related]
10. TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma.
Mosrati MA; Malmström A; Lysiak M; Krysztofiak A; Hallbeck M; Milos P; Hallbeck AL; Bratthäll C; Strandéus M; Stenmark-Askmalm M; Söderkvist P
Oncotarget; 2015 Jun; 6(18):16663-73. PubMed ID: 26143636
[TBL] [Abstract][Full Text] [Related]
11. TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
Williams EA; Miller JJ; Tummala SS; Penson T; Iafrate AJ; Juratli TA; Cahill DP
Acta Neuropathol Commun; 2018 Oct; 6(1):106. PubMed ID: 30333046
[TBL] [Abstract][Full Text] [Related]
12. New prognostic factor telomerase reverse transcriptase promotor mutation presents without MR imaging biomarkers in primary glioblastoma.
Ersoy TF; Keil VC; Hadizadeh DR; Gielen GH; Fimmers R; Waha A; Heidenreich B; Kumar R; Schild HH; Simon M
Neuroradiology; 2017 Dec; 59(12):1223-1231. PubMed ID: 28894890
[TBL] [Abstract][Full Text] [Related]
13. TERT promoter mutations in primary and secondary glioblastomas.
Nonoguchi N; Ohta T; Oh JE; Kim YH; Kleihues P; Ohgaki H
Acta Neuropathol; 2013 Dec; 126(6):931-7. PubMed ID: 23955565
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of the isocitrate dehydrogenase gene and telomerase reverse transcriptase promoter mutations in gliomas in Chinese patients.
Qu CX; Ji HM; Shi XC; Bi H; Zhai LQ; Han DW
Brain Behav; 2020 Apr; 10(4):e01583. PubMed ID: 32146731
[TBL] [Abstract][Full Text] [Related]
15. TERT promoter mutations in soft tissue sarcomas.
Campanella NC; Penna V; Abrahão-Machado LF; Cruvinel-Carloni A; Ribeiro G; Soares P; Scapulatempo-Neto C; Reis RM
Int J Biol Markers; 2016 Feb; 31(1):e62-7. PubMed ID: 26391479
[TBL] [Abstract][Full Text] [Related]
16. The TERT promoter SNP rs2853669 decreases E2F1 transcription factor binding and increases mortality and recurrence risks in liver cancer.
Ko E; Seo HW; Jung ES; Kim BH; Jung G
Oncotarget; 2016 Jan; 7(1):684-99. PubMed ID: 26575952
[TBL] [Abstract][Full Text] [Related]
17. Highly sensitive detection of TERT promoter mutations in recurrent glioblastomas using digital PCR.
Miki S; Satomi K; Ohno M; Matsushita Y; Kitahara M; Miyakita Y; Takahashi M; Matsuda M; Ishikawa E; Matsumura A; Yoshida A; Narita Y; Ichimura K
Brain Tumor Pathol; 2020 Oct; 37(4):154-158. PubMed ID: 32749624
[TBL] [Abstract][Full Text] [Related]
18. New somatic TERT promoter variants enhance the Telomerase activity in Glioblastoma.
Pierini T; Nardelli C; Lema Fernandez AG; Pierini V; Pellanera F; Nofrini V; Gorello P; Moretti M; Arniani S; Roti G; Giovenali P; Lupattelli M; Metro G; Molica C; Castrioto C; Corinaldesi R; Laurenti ME; Ascani S; Mecucci C; La Starza R
Acta Neuropathol Commun; 2020 Aug; 8(1):145. PubMed ID: 32843091
[TBL] [Abstract][Full Text] [Related]
19. TERT promoter mutated WHO grades II and III gliomas are located preferentially in the frontal lobe and avoid the midline.
Sun ZL; Chan AK; Chen LC; Tang C; Zhang ZY; Ding XJ; Wang Y; Sun CR; Ng HK; Yao Y; Zhou LF
Int J Clin Exp Pathol; 2015; 8(9):11485-94. PubMed ID: 26617880
[TBL] [Abstract][Full Text] [Related]
20. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss.
Arita H; Narita Y; Fukushima S; Tateishi K; Matsushita Y; Yoshida A; Miyakita Y; Ohno M; Collins VP; Kawahara N; Shibui S; Ichimura K
Acta Neuropathol; 2013 Aug; 126(2):267-76. PubMed ID: 23764841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
